Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2024-06-06
2031-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be asked to provide clinical information and various tissues (saliva, gastric mucosa, and feces).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Samsung Medical Center-Lymphoma Cohort Study-II
NCT01877109
Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma
NCT01341119
Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
NCT03578198
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
NCT03117036
Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study
NCT02691351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MALT lymphoma
Patients who were newly diagnosed as gastric MALT lymphoma
MALT lymphoma
New diagnosis with gastric MALT lymphoma
Control group
Patients who underwent
1. diagnosed upper endoscopy for dyspepsia and had chronic gastritis,
2. therapeutic upper endoscopy for gastric hyperplastic polyps, or
3. screening upper endoscopy without any symptoms.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MALT lymphoma
New diagnosis with gastric MALT lymphoma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed as gastric MALT lymphoma \[Control group\]
* Patients who underwent
1. diagnosed upper endoscopy for dyspepsia and had chronic gastritis,
2. therapeutic upper endoscopy for gastric hyperplastic polyps, or
3. screening upper endoscopy without any symptoms.
Exclusion Criteria
* Use of antibiotics or probiotics within 4 weeks
* Uncontrolled chronic illnesses
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kangbuk Samsung Hospital
OTHER
Korea University Ansan Hospital
OTHER
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cheol Min Shin
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Ansan Hospital
Ansan-si, Gyeonggi-do, South Korea
Cheol Min Shin
Seongnam-si, Gyeonggi-do, South Korea
Kangbuk Samsung Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M; ESMO Guidelines Committee. Electronic address: [email protected]. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. Epub 2019 Dec 4. No abstract available.
Di Rocco A, Petrucci L, Assanto GM, Martelli M, Pulsoni A. Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment. Cancers (Basel). 2022 Mar 29;14(7):1742. doi: 10.3390/cancers14071742.
Tanaka T, Matsuno Y, Torisu T, Shibata H, Hirano A, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Moriyama T, Esaki M, Kitazono T. Gastric microbiota in patients with Helicobacter pylori-negative gastric MALT lymphoma. Medicine (Baltimore). 2021 Sep 24;100(38):e27287. doi: 10.1097/MD.0000000000027287.
Lemos FFB, Silva Luz M, Rocha Pinheiro SL, Teixeira KN, Freire de Melo F. Role of non-Helicobacter pylori gastric Helicobacters in helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol. 2023 Aug 28;29(32):4851-4859. doi: 10.3748/wjg.v29.i32.4851.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUG-MALToma
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.